Literature DB >> 17132762

Induction of glutathione synthesis explains pharmacodynamics of high-dose busulfan in mice and highlights putative mechanisms of drug interaction.

Jérôme Bouligand1, Alain Deroussent, Nicolas Simonnard, Paule Opolon, Jackie Morizet, Elisabeth Connault, Estelle Daudigeos, Micheline Re, Angelo Paci, Gilles Vassal.   

Abstract

Busulfan is an example of a drug eliminated through glutathione S-transferase (GST)-catalyzed conjugation with reduced glutathione (GSH). We studied the pharmacokinetics and toxicity of busulfan in C57BL6 mice in correlation with liver GST activity and GSH synthesis by accurate determination of precursors, namely, gamma-glutamyl-cysteine and cysteine. A significantly lower incidence of acute toxicity was observed in mice receiving busulfan 16.5 mg/kg twice a day compared with animals receiving 33 mg/kg once a day. In both cases, a total dose of 132 mg/kg was administered over 4 days. The difference in toxicity was explained by pharmacokinetics since a strong induction of clearance was observed only in animals treated twice daily. Induction of metabolism was correlated with an increase in liver cysteine content and enhanced glutathione synthesis rate, whereas GST activity was unchanged. To our knowledge, this is the first time that in vivo flux of GSH synthesis has been shown to be closely related to a drug plasma clearance and toxicity. These results allow hypothesizing that GSH liver synthesis may directly influence busulfan clearance in humans with possible implications in the occurrence of hepatic veno-occlusive disease.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17132762     DOI: 10.1124/dmd.106.012880

Source DB:  PubMed          Journal:  Drug Metab Dispos        ISSN: 0090-9556            Impact factor:   3.922


  9 in total

1.  Antineoplastic agent busulfan regulates a network of genes related to coagulation and fibrinolysis.

Authors:  Janka Reimer; Sandra Bien; Sabine Ameling; Elke Hammer; Uwe Völker; Georg Hempel; Joachim Boos; Heyo K Kroemer; Christoph A Ritter
Journal:  Eur J Clin Pharmacol       Date:  2012-06       Impact factor: 2.953

Review 2.  Reversible and irreversible protein glutathionylation: biological and clinical aspects.

Authors:  Arthur Jl Cooper; John T Pinto; Patrick S Callery
Journal:  Expert Opin Drug Metab Toxicol       Date:  2011-05-11       Impact factor: 4.481

3.  Iron Overload Exacerbates Busulfan-Melphalan Toxicity Through a Pharmacodynamic Interaction in Mice.

Authors:  Jérôme Bouligand; Clémentine Richard; Dominique Valteau-Couanet; Cedric Orear; Lionel Mercier; Romain Kessari; Nicolas Simonnard; Fabienne Munier; Estelle Daudigeos-Dubus; Bassim Tou; Paule Opolon; Alain Deroussent; Angelo Paci; Gilles Vassal
Journal:  Pharm Res       Date:  2016-04-18       Impact factor: 4.200

4.  Dehydroalanine analog of glutathione: an electrophilic busulfan metabolite that binds to human glutathione S-transferase A1-1.

Authors:  Islam R Younis; Meenal Elliott; Cody J Peer; Arthur J L Cooper; John T Pinto; Gregory W Konat; Michal Kraszpulski; William P Petros; Patrick S Callery
Journal:  J Pharmacol Exp Ther       Date:  2008-09-12       Impact factor: 4.030

Review 5.  Clarifying busulfan metabolism and drug interactions to support new therapeutic drug monitoring strategies: a comprehensive review.

Authors:  Alan L Myers; Jitesh D Kawedia; Richard E Champlin; Mark A Kramer; Yago Nieto; Romi Ghose; Borje S Andersson
Journal:  Expert Opin Drug Metab Toxicol       Date:  2017-08-17       Impact factor: 4.481

6.  Association of CTH variant with sinusoidal obstruction syndrome in children receiving intravenous busulfan and cyclophosphamide before hematopoietic stem cell transplantation.

Authors:  P Huezo-Diaz Curtis; C R S Uppugunduri; J Muthukumaran; M A Rezgui; C Peters; P Bader; M Duval; H Bittencourt; Maja Krajinovic; Marc Ansari
Journal:  Pharmacogenomics J       Date:  2016-10-25       Impact factor: 3.550

Review 7.  Glutathione transferases: substrates, inihibitors and pro-drugs in cancer and neurodegenerative diseases.

Authors:  Nerino Allocati; Michele Masulli; Carmine Di Ilio; Luca Federici
Journal:  Oncogenesis       Date:  2018-01-24       Impact factor: 7.485

Review 8.  Management of toxicities associated with novel immunotherapy agents in acute lymphoblastic leukemia.

Authors:  Tania Jain; Mark R Litzow
Journal:  Ther Adv Hematol       Date:  2020-01-20

9.  Spermatogonial stem cell transplantation into nonablated mouse recipient testes.

Authors:  Hiroko Morimoto; Narumi Ogonuki; Mito Kanatsu-Shinohara; Shogo Matoba; Atsuo Ogura; Takashi Shinohara
Journal:  Stem Cell Reports       Date:  2021-06-17       Impact factor: 7.765

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.